Grigorios Siokas Purchases 493,495 Shares of Cosmos Health (NASDAQ:COSM) Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas bought 493,495 shares of Cosmos Health stock in a transaction dated Wednesday, January 14th. The shares were bought at an average cost of $0.45 per share, with a total value of $222,072.75. Following the completion of the transaction, the chief executive officer directly owned 7,738,474 shares in the company, valued at approximately $3,482,313.30. This trade represents a 6.81% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Grigorios Siokas also recently made the following trade(s):

• On Monday, January 12th, Grigorios Siokas acquired 113,185 shares of Cosmos Health stock. The stock was purchased at an average price of $0.50 per share, for a total transaction of $56,592.50.
• On Thursday, January 8th, Grigorios Siokas acquired 156,190 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.52 per share, with a total value of $81,218.80.
• On Wednesday, January 7th, Grigorios Siokas bought 124,880 shares of Cosmos Health stock. The stock was purchased at an average cost of $0.52 per share, with a total value of $64,937.60.
• On Tuesday, January 6th, Grigorios Siokas bought 133,953 shares of Cosmos Health stock. The stock was purchased at an average price of $0.54 per share, for a total transaction of $72,334.62.
• On Friday, December 19th, Grigorios Siokas purchased 88,314 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.49 per share, for a total transaction of $43,273.86.
• On Monday, December 15th, Grigorios Siokas purchased 168,472 shares of Cosmos Health stock. The shares were purchased at an average price of $0.42 per share, with a total value of $70,758.24.
• On Friday, November 28th, Grigorios Siokas acquired 76,360 shares of Cosmos Health stock. The stock was purchased at an average price of $0.64 per share, for a total transaction of $48,870.40.
• On Tuesday, November 25th, Grigorios Siokas acquired 55,732 shares of Cosmos Health stock. The shares were acquired at an average cost of $0.63 per share, for a total transaction of $35,111.16.
• On Friday, November 21st, Grigorios Siokas bought 56,080 shares of Cosmos Health stock. The shares were acquired at an average price of $0.68 per share, with a total value of $38,134.40.
• On Thursday, November 20th, Grigorios Siokas bought 51,315 shares of Cosmos Health stock. The stock was acquired at an average price of $0.62 per share, with a total value of $31,815.30.

Cosmos Health Stock Performance

NASDAQ COSM opened at $0.52 on Friday. The firm has a market cap of $19.63 million, a P/E ratio of -0.70 and a beta of 5.37. The company has a quick ratio of 0.84, a current ratio of 0.99 and a debt-to-equity ratio of 0.25. The company’s 50 day moving average is $0.55 and its 200-day moving average is $0.73. Cosmos Health Inc. has a 12-month low of $0.28 and a 12-month high of $1.32.

Cosmos Health (NASDAQ:COSM) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.16). The business had revenue of $17.11 million during the quarter, compared to analysts’ expectations of $16.40 million. Cosmos Health had a negative net margin of 31.01% and a negative return on equity of 33.19%. Sell-side analysts predict that Cosmos Health Inc. will post -0.78 earnings per share for the current year.

More Cosmos Health News

Here are the key news stories impacting Cosmos Health this week:

• Positive Sentiment: Significant CEO insider accumulation — CEO Grigorios Siokas disclosed a purchase of 493,495 shares at ~$0.45 on Jan. 14 (raising his stake ~6.8%), adding to multiple buys earlier in January; heavy insider buying signals management confidence and likely underpins short‑term buying interest. Read More.
• Positive Sentiment: Zacks Small‑Cap initiation with optimistic projections — Zacks initiated coverage and models revenue growth (~$130M+ by 2027) and a path to positive EPS by FY2027, which is a near‑term sentiment booster for a micro‑cap stock. Read More.
• Positive Sentiment: Growing institutional interest — filings show funds (e.g., Citadel) increased positions recently, which can improve liquidity and provide steady demand for shares. Read More.
• Neutral Sentiment: Zacks’ forward EPS trajectory is model‑driven — the research projects FY2027 EPS ~ $0.07, but these estimates depend on execution (U.S. expansion, AI R&D, product rollouts) and are not confirmed results. Read More.
• Negative Sentiment: Recent fundamentals remain weak — the company missed on EPS in its last report, posts negative margins and ROE, and consensus still forecasts a full‑year loss (~‑$0.78), keeping near‑term earnings risk elevated. Read More.
• Negative Sentiment: Valuation and disclosure caveats — Zacks used a high discount rate in its model and the report was paid/sponsored, which raises impartiality and model‑assumption risk for investors. Read More.
• Negative Sentiment: High volatility and small‑cap risk — COSM’s tiny market cap and high beta make the share price prone to sharp swings; broker coverage is limited and consensus ratings skew toward Sell, increasing trading risk. Read More.

Analysts Set New Price Targets

COSM has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cosmos Health in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Cosmos Health to a “hold” rating in a research report on Saturday, September 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Trading of Cosmos Health

A hedge fund recently raised its stake in Cosmos Health stock. Citadel Advisors LLC lifted its holdings in shares of Cosmos Health Inc. (NASDAQ:COSM) by 133.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 225,507 shares of the company’s stock after purchasing an additional 128,776 shares during the quarter. Citadel Advisors LLC owned 0.65% of Cosmos Health worth $250,000 at the end of the most recent quarter. Institutional investors and hedge funds own 12.61% of the company’s stock.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.